Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$27.58 USD

27.58
3,889,579

-0.60 (-2.13%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $27.00 -0.58 (-2.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Perrigo (PRGO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Perrigo (PRGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Procter & Gamble Rewards Investors Amid Coronavirus Despair

Although U.S. companies are reeling under the uncertain impacts of the coronavirus, Procter & Gamble's (PG) recent move to hike dividend comes as a sigh of relief for investors.

Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results

Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.

Sanofi to Withdraw Zantac After FDA Warns of Carcinogens

The FDA requests drugmakers to withdraw all ranitidine medications, which includes Sanofi's (SNY) popular heartburn drug Zantac, due to possible increase in risk of cancer.

Why Is Perrigo (PRGO) Down 11% Since Last Earnings Report?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Trina Mukherjee headshot

Medical Products Industry Outlook: Growth Prospects Bright

Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.

Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues

Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.

Perrigo (PRGO) Lags Q4 Earnings Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -2.75% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?

Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.

Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2019 results.

Is a Beat in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

InMode (INMD) to Post Q4 Earnings: What's in the Cards?

InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.

Here's Why You Should Add ResMed (RMD) to Your Portfolio

Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.

QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe

QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.

PRGO or PAHC: Which Is the Better Value Stock Right Now?

PRGO vs. PAHC: Which Stock Is the Better Value Option?

Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark

Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.

Align (ALGN) Rides on Volume Expansion Despite Cost Concerns

We are upbeat about Align's (ALGN) consistent uptrend in Invisalign volumes across all geographies.

Here's Why You Should Hold on to Hologic (HOLX) Stock for Now

Investors continue to be optimistic about Hologic (HOLX) on its strong segmental and international results in Q1.

Will Perrigo (PRGO) Beat Estimates Again in Its Next Earnings Report?

Perrigo (PRGO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod

Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.

PRGO vs. PAHC: Which Stock Should Value Investors Buy Now?

PRGO vs. PAHC: Which Stock Is the Better Value Option?